{"id":"https://openalex.org/W2396932993","doi":"https://doi.org/10.1037/e496132006-005","title":"Assessment of Buprenorphine in a Drug Discrimination Procedure in Humans","display_name":"Assessment of Buprenorphine in a Drug Discrimination Procedure in Humans","publication_year":1992,"publication_date":"1992-01-01","ids":{"openalex":"https://openalex.org/W2396932993","doi":"https://doi.org/10.1037/e496132006-005","mag":"2396932993","pmid":"https://pubmed.ncbi.nlm.nih.gov/1406908"},"language":"en","primary_location":{"id":"doi:10.1037/e496132006-005","doi":"https://doi.org/10.1037/e496132006-005","is_oa":false,"landing_page_url":"https://doi.org/10.1037/e496132006-005","pdf_url":null,"source":{"id":"https://openalex.org/S4306524878","display_name":"PsycEXTRA Dataset","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PsycEXTRA Dataset","raw_type":"dataset"},"volume":null,"type":"dataset","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072239291","display_name":"George E. Bigelow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]},{"id":"https://openalex.org/I2802697821","display_name":"Johns Hopkins Bayview Medical Center","ror":"https://ror.org/04pwc8466","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436","https://openalex.org/I2802697821"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George E. Bigelow","raw_affiliation_strings":["Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Francis Scott Key Medical Center, Baltimore, MD 21224"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Francis Scott Key Medical Center, Baltimore, MD 21224","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I2799853436","https://openalex.org/I2802697821"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060972692","display_name":"Kenzie L. Preston","orcid":"https://orcid.org/0000-0003-0603-2479","observed_orcids":["https://orcid.org/0000-0003-0603-2479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenzie L. Preston","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"121","issue":null,"first_page":"28","last_page":"37"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.6279000043869019,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.6279000043869019,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":0.22709999978542328,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.07479999959468842,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/buprenorphine","display_name":"buprenorphine","score":1.0},{"id":"https://openalex.org/keywords/drug-discrimination","display_name":"drug discrimination","score":0.9039999842643738},{"id":"https://openalex.org/keywords/hydromorphone","display_name":"hydromorphone","score":0.9639999866485596},{"id":"https://openalex.org/keywords/pentazocine","display_name":"pentazocine","score":0.9070000052452087},{"id":"https://openalex.org/keywords/butorphanol","display_name":"butorphanol","score":0.9950000047683716},{"id":"https://openalex.org/keywords/nalbuphine","display_name":"nalbuphine","score":1.0},{"id":"https://openalex.org/keywords/subjective-effects","display_name":"subjective effects","score":0.6629999876022339},{"id":"https://openalex.org/keywords/stimulus-generalization","display_name":"stimulus generalization","score":0.6499999761581421},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C2779158186","wikidata":"https://www.wikidata.org/wiki/Q303646","display_name":"Hydromorphone","level":4,"score":0.9628157615661621},{"id":"https://openalex.org/C2778949969","wikidata":"https://www.wikidata.org/wiki/Q407721","display_name":"Buprenorphine","level":4,"score":0.9281567931175232},{"id":"https://openalex.org/C2781020239","wikidata":"https://www.wikidata.org/wiki/Q1185089","display_name":"Butorphanol","level":2,"score":0.9152486324310303},{"id":"https://openalex.org/C2778977083","wikidata":"https://www.wikidata.org/wiki/Q277979","display_name":"Nalbuphine","level":4,"score":0.8898262977600098},{"id":"https://openalex.org/C2780802079","wikidata":"https://www.wikidata.org/wiki/Q415793","display_name":"Pentazocine","level":3,"score":0.8822368383407593},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7418354749679565},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.6862747669219971},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.47558653354644775},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47392377257347107},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40897345542907715},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3981148302555084},{"id":"https://openalex.org/C2777389121","wikidata":"https://www.wikidata.org/wiki/Q81225","display_name":"Morphine","level":2,"score":0.3807641267776489},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13640189170837402},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07860255241394043}],"mesh":[{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004192","descriptor_name":"Discrimination, Psychological","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1037/e496132006-005","doi":"https://doi.org/10.1037/e496132006-005","is_oa":false,"landing_page_url":"https://doi.org/10.1037/e496132006-005","pdf_url":null,"source":{"id":"https://openalex.org/S4306524878","display_name":"PsycEXTRA Dataset","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PsycEXTRA Dataset","raw_type":"dataset"},{"id":"pmid:1406908","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/1406908","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NIDA research monograph","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8999999761581421,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5600000023841858,"id":"https://metadata.un.org/sdg/16","display_name":"Peace, justice, and strong institutions"},{"score":0.46000000834465027,"id":"https://metadata.un.org/sdg/10","display_name":"Reduced inequalities"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1797983429","display_name":null,"funder_award_id":"DA 00050","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G4628939522","display_name":"BEHAVIORAL PHARMACOLOGICAL AIDS PREVENTION","funder_award_id":"5r18da006120-05","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G502352582","display_name":null,"funder_award_id":"DA-04089","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G576134281","display_name":"OPIOID DRUG DISCRIMINATION","funder_award_id":"5r01da004089-12","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G798437548","display_name":null,"funder_award_id":"DA06120","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2160045838","https://openalex.org/W2325897487","https://openalex.org/W2167675390","https://openalex.org/W2091421021","https://openalex.org/W2257112069","https://openalex.org/W1829823113","https://openalex.org/W7098357079","https://openalex.org/W1984284193","https://openalex.org/W2013597991","https://openalex.org/W2083312086"],"abstract_inverted_index":{"These":[0,203],"studies":[1,92],"indicate":[2],"that":[3,13,64,68,150,154,171,192,210,231,242,254],"buprenorphine":[4,19,58,110,149,211],"shares":[5],"stimulus":[6,247],"effects":[7,18,167,191,230,248],"with":[8,185,207],"other":[9,28,71,157,200],"opioid":[10,29],"drugs":[11],"and":[12,34,46,93,100,249],"in":[14,90,95,120,127],"overall":[15],"profile":[16,163,244],"of":[17,62,69,146,164,172,188,195,198,228,235,245,255],"is":[20,38,212],"more":[21],"similar":[22,169,252],"to":[23,79,88,107,117,135,148,155,170,253],"hydromorphone":[24,89,118,123],"than":[25],"are":[26,193,205],"the":[27,41,48,54,70,121,130,156,189,199,208,217,224,256],"mixed":[30,132,158,201],"agonist-antagonists":[31,133],"tested-pentazocine,":[32],"butorphanol,":[33,83,108],"nalbuphine.":[35],"This":[36],"characterization":[37],"supported":[39],"by":[40,47],"behavioral":[42],"drug":[43,55],"discrimination":[44,56,126],"results":[45],"subjective":[49,138,166,183,250],"effect":[50,139],"self-report":[51,140],"results.":[52],"In":[53,160],"assessments":[57],"showed":[59,102,114],"a":[60,96,144,213,236],"pattern":[61,145],"generalization":[63,106,116],"was":[65,151,168],"different":[66,152],"from":[67,153],"opioid-mixed":[72],"agonist-antagonists.":[73,159,202],"It":[74],"did":[75,86,111],"not":[76,222],"generalize":[77,87],"completely":[78],"either":[80],"pentazocine":[81,101],"or":[82],"but":[84,109],"it":[85],"two":[91],"partially":[94],"third.":[97],"Both":[98],"nalbuphine":[99],"at":[103,216],"least":[104],"partial":[105,214,237],"not.":[112],"Butorphanol":[113],"little":[115,186],"except":[119],"two-choice":[122],"vs.":[124],"saline":[125],"which":[128],"all":[129],"tested":[131],"generalized":[134],"hydromorphone.":[136,173,259],"The":[137],"data":[141,204],"also":[142],"revealed":[143],"response":[147],"particular,":[161],"buprenorphine's":[162,243],"acute":[165],"There":[174],"were":[175],"dose-related":[176],"increases":[177],"on":[178,226],"various":[179],"scales":[180],"reflecting":[181],"positive":[182],"effects,":[184],"evidence":[187],"dysphoric":[190],"characteristic":[194,234],"high":[196],"doses":[197],"compatible":[206],"view":[209],"agonist":[215],"mu-receptor.":[218],"Although":[219],"they":[220,239],"do":[221,240],"demonstrate":[223,241],"ceiling":[225],"magnitude":[227],"pharmacological":[229],"would":[232],"be":[233],"agonist,":[238],"activity--both":[246],"effects--is":[251],"pure":[257],"mu-agonist":[258]},"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}